Synthetic Biologics Reports 2011 Year End Financial Results
— Company Prioritizes Focus on Synthetic DNA-Based Therapeutics — ANN ARBOR, Mich., March 30, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the year ended December 31, 2011 and summarized operational highlights. Operational Highlights Synthetic Biologics […]
Synthetic Biologics Reports 2011 Year End Financial Results Read More »